Skip Ribbon Commands
Skip to main content
Navigate Up
Search
Test Code
Search
Laboratory Section
Test Category
Browse By Test Name
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/-II) Antibody Screen with Confirmation, Serum
Test Code: HTLVSO
Synonyms/Keywords
​Lab Ref Code:  9539, HTLV I/II Ab
Useful For
​Qualitative detection of human T-cell lymphotropic virus types I and II (HTLV-I and HTLV-II)-specific antibodies with confirmation and differentiation between HTLV-I and HTLV-II infection
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Serum Separator Tube (SST) ​Red Top Tube (RTT) 1 mL​ ​0.6 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum​ Frozen (preferred)​ ​28 days
​Refrigerated 7 days​
Rejection Criteria
GrossH Hemolysis
Gross ​Lipemia​
Gross Icterus​
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​​
HTLV-I/-II Antibody Screen: Monday through Friday; varies
HTLV-I/-II Antibody Confirmation: Wednesday; 3:00 p.m.
2 days​

 Enzyme Immunoassay (EIA)


Confirmation by Western Blot

Reference Lab
Test Information

   

Reference Range Information
Performing Location Reference Range
Mayo Medical Laboratories​​ Negative​
Interpretation
Negative screening results indicate the absence of both human T-cell lymphotropic virus types I and II (HTLV-I- and HTLV-II)-specific IgG antibodies in serum.
 
A reactive screening test result is suggestive of infection with either HTLV-I or HTLV-II. However, this result does not confirm infection (eg, low specificity), and it cannot differentiate between HTLV-I and HTLV-II infection.
 
Specimens with reactive screening test results will be tested automatically by the line immunoassay (LIA) confirmatory test. Positive LIA results provide confirmatory evidence of infection with HTLV-I or HTLV-II.
-Positive results for HTLV-I antibodies indicate the confirmed presence of HTLV-I IgG antibodies in serum, based on 2 visible antibody bands that include gp21-I/-II band, or 3 or more bands, and the sum of the gp46-I and p19-I band intensity is greater than the gp46-II band intensity.
-Positive results for HTLV-II antibodies indicate the confirmed presence of HTLV-II IgG antibodies in serum, based on 2 visible antibody bands that include gp21-I/-II band, or 3 or more bands, and the gp46-II band intensity is a) greater than the gp46-I band intensity and b) > or =the sum of the gp46-I and p19-I band intensity.
 
Indeterminate LIA results indicate the presence of gp21-I/-II band only or combination of any 2 bands without a detectable gp21-I/-II band. Patients with indeterminate test results with known risk factors for HTLV-I or HTLV-II infection should undergo repeat confirmatory antibody testing in 1 to 2 months to determine final infection status.
 
When the LIA band intensity pattern does not meet the criteria of a positive HTLV-I- or HTLV-II-antibody band intensity pattern, differentiation of HTLV-I and HTLV-II infection is not possible (ie, nontypeable HTLV antibodies).
 
A reactive screening result with a negative or indeterminate confirmatory test result suggests either a false-reactive screening test result or a seroconverting HTLV infection. Repeat testing in 1 to 2 months can clarify the final infection status. Persistently indeterminate confirmatory test results indicate absence of HTLV infection.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
86790 ​1 ​Screen
​86689 ​1 ​Confirm ​​If needed
Classification

   

Synonyms/Keywords
​Lab Ref Code:  9539, HTLV I/II Ab
Ordering Applications
Ordering Application Description
​Centricity ​HTLV I/II Ab Serum
​Cerner ​HTLV-I Antibody (9539)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Serum Separator Tube (SST) ​Red Top Tube (RTT) 1 mL​ ​0.6 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum​ Frozen (preferred)​ ​28 days
​Refrigerated 7 days​
Rejection Criteria
GrossH Hemolysis
Gross ​Lipemia​
Gross Icterus​
Useful For
​Qualitative detection of human T-cell lymphotropic virus types I and II (HTLV-I and HTLV-II)-specific antibodies with confirmation and differentiation between HTLV-I and HTLV-II infection
Test Information

   

Reference Range Information
Performing Location Reference Range
Mayo Medical Laboratories​​ Negative​
Interpretation
Negative screening results indicate the absence of both human T-cell lymphotropic virus types I and II (HTLV-I- and HTLV-II)-specific IgG antibodies in serum.
 
A reactive screening test result is suggestive of infection with either HTLV-I or HTLV-II. However, this result does not confirm infection (eg, low specificity), and it cannot differentiate between HTLV-I and HTLV-II infection.
 
Specimens with reactive screening test results will be tested automatically by the line immunoassay (LIA) confirmatory test. Positive LIA results provide confirmatory evidence of infection with HTLV-I or HTLV-II.
-Positive results for HTLV-I antibodies indicate the confirmed presence of HTLV-I IgG antibodies in serum, based on 2 visible antibody bands that include gp21-I/-II band, or 3 or more bands, and the sum of the gp46-I and p19-I band intensity is greater than the gp46-II band intensity.
-Positive results for HTLV-II antibodies indicate the confirmed presence of HTLV-II IgG antibodies in serum, based on 2 visible antibody bands that include gp21-I/-II band, or 3 or more bands, and the gp46-II band intensity is a) greater than the gp46-I band intensity and b) > or =the sum of the gp46-I and p19-I band intensity.
 
Indeterminate LIA results indicate the presence of gp21-I/-II band only or combination of any 2 bands without a detectable gp21-I/-II band. Patients with indeterminate test results with known risk factors for HTLV-I or HTLV-II infection should undergo repeat confirmatory antibody testing in 1 to 2 months to determine final infection status.
 
When the LIA band intensity pattern does not meet the criteria of a positive HTLV-I- or HTLV-II-antibody band intensity pattern, differentiation of HTLV-I and HTLV-II infection is not possible (ie, nontypeable HTLV antibodies).
 
A reactive screening result with a negative or indeterminate confirmatory test result suggests either a false-reactive screening test result or a seroconverting HTLV infection. Repeat testing in 1 to 2 months can clarify the final infection status. Persistently indeterminate confirmatory test results indicate absence of HTLV infection.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​​
HTLV-I/-II Antibody Screen: Monday through Friday; varies
HTLV-I/-II Antibody Confirmation: Wednesday; 3:00 p.m.
2 days​

 Enzyme Immunoassay (EIA)


Confirmation by Western Blot

Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
86790 ​1 ​Screen
​86689 ​1 ​Confirm ​​If needed
Classification

   

For most current information refer to the Marshfield Laboratory online reference manual.